These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32079135)

  • 1. Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database.
    Chiappini S; Schifano F; Corkery JM; Guirguis A
    Brain Sci; 2020 Feb; 10(2):. PubMed ID: 32079135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the 2004-2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems.
    Schifano F; Chiappini S; Corkery JM; Guirguis A
    Front Pharmacol; 2019; 10():46. PubMed ID: 30774595
    [No Abstract]   [Full Text] [Related]  

  • 3. An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions.
    Schifano F; Chiappini S; Corkery JM; Guirguis A
    Int J Neuropsychopharmacol; 2019 Apr; 22(4):270-277. PubMed ID: 30722037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is There a Potential of Misuse for Venlafaxine and Bupropion?
    Schifano F; Chiappini S
    Front Pharmacol; 2018; 9():239. PubMed ID: 29618978
    [No Abstract]   [Full Text] [Related]  

  • 5. Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database.
    Chiappini S; Schifano F
    J Clin Psychopharmacol; 2018 Feb; 38(1):72-79. PubMed ID: 29210868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS).
    Chiappini S; Vickers-Smith R; Guirguis A; Corkery JM; Martinotti G; Harris DR; Schifano F
    Pharmaceuticals (Basel); 2022 May; 15(6):. PubMed ID: 35745593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases.
    Chiappini S; Vickers-Smith R; Guirguis A; Corkery JM; Martinotti G; Schifano F
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond the 'purple drank': Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports.
    Chiappini S; Schifano F; Corkery JM; Guirguis A
    J Psychopharmacol; 2021 Jun; 35(6):681-692. PubMed ID: 33427017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports.
    Schifano F; Chiappini S
    PLoS One; 2018; 13(10):e0204443. PubMed ID: 30286103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-2 Agonists as Misusing Drugs? Assessment of both Clenbuterol- and Salbutamol-related European Medicines Agency Pharmacovigilance Database Reports.
    Milano G; Chiappini S; Mattioli F; Martelli A; Schifano F
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):182-187. PubMed ID: 29498199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports.
    Schifano N; Chiappini S; Castiglione F; Salonia A; Schifano F
    Low Urin Tract Symptoms; 2021 Apr; 13(2):230-237. PubMed ID: 33037767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance.
    Sagud M; Breznoscakova D; Celofiga A; Chihai J; Chkonia E; Ristic Ignjatovic D; Injac Stevovic L; Kopecek M; Kurvits K; Kuzo N; Lazáry J; Mazaliauskienė R; Mladina Perisa D; Novotni A; Panov G; Pikirenia U; Rădulescu FȘ; Sukiasyan SG; Taube M; Tomori S; Wilkowska A; De Las Cuevas C; Sanz EJ; de Leon J
    Schizophr Res; 2024 Jun; 268():53-59. PubMed ID: 37783650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia).
    De Las Cuevas C; Sanz EJ; de Leon J
    Schizophr Res; 2024 Jun; 268():165-174. PubMed ID: 37301669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK.
    De Las Cuevas C; Sanz EJ; Gross JA; Correll CU; Verdoux H; Lally J; de Filippis R; Schulte PFJ; Molden E; Arrojo-Romero M; Bostrom AD; Schoretsanitis G; Fernandez-Egea E; de Leon J
    Schizophr Res; 2024 Jun; 268():175-188. PubMed ID: 38065799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.
    Chiappini S; Schifano F
    CNS Drugs; 2016 Jul; 30(7):647-54. PubMed ID: 27312320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance.
    Baptista T; Motuca M; Serrano A; Perez Lo Presti A; Fernandez-Arana A; Olmos I; Pabon A; Yepez JGA; Alejo Galarza GJ; Rivera Ramirez NM; Elkis H; Sanz EJ; De Las Cuevas C; de Leon J
    Schizophr Res; 2024 Jun; 268():60-65. PubMed ID: 37985318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of major adverse events of clozapine based on accordance to an international titration guideline.
    Nuebel M; Leung JG; Hughes C; McGrane I
    Ment Health Clin; 2024 Jun; 14(3):204-211. PubMed ID: 38835819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
    Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
    Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Drug Reactions to Opioids: A Study in a National Pharmacovigilance Database.
    Gustafsson M; Matos C; Joaquim J; Scholl J; van Hunsel F
    Drug Saf; 2023 Nov; 46(11):1133-1148. PubMed ID: 37824028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.